Arcus Biosciences' Clinical Setback Triggers Stock Pullback Amid Strategic Pivot

Arcus Biosciences, Inc. [RCUS] faced a significant market correction after announcing the termination of its STAR-221 phase III trial, which had been developed in partnership with Gilead Sciences, Inc. [GILD]. The stock tumbled 14.4% on the news, though year-to-date performance remained solid at 44.6% gains versus the broader industry’s 18.2% advance.

The decision to halt the STAR-221 program came following an independent data monitoring committee review that determined the domvanalimab-based treatment regimen failed to deliver meaningful survival improvements over the standard-of-care approach. This represents a significant pivot for Arcus and its long-standing collaboration with Gilead, which began in 2020 and underwent restructuring in 2024.

Understanding the Failed Trial Design

The STAR-221 study examined domvanalimab—an anti-TIGIT antibody designed to enhance immune checkpoint function—when combined with zimberelimab (anti-PD-1 antibody) and chemotherapy. The investigational combination was tested against Opdivo (nivolumab) plus chemotherapy as a first-line treatment for patients with advanced gastric and esophageal cancers.

The interim analysis of overall survival data revealed that the dual-antibody approach failed to outperform the nivolumab-chemotherapy backbone. While the safety profile proved comparable to the control arm with no novel adverse events identified, efficacy shortfall necessitated termination. Related phase II EDGE-Gastric studies will also be discontinued.

Gilead and Arcus subsequently reprioritized their joint development strategy in 2024, shifting focus toward indications where domvanalimab combination therapy might deliver greater clinical benefit through broader patient enrollment designs and high unmet medical need settings.

Redirecting Development Toward Renal Cell Carcinoma

Rather than pursuing further TIGIT-targeted oncology programs, Arcus is accelerating its development timeline for casdatifan, a HIF-2α inhibitor candidate demonstrating robust single-agent activity in late-line clear cell renal cell carcinoma (ccRCC). Data from the ongoing ARC-20 phase I/Ib trial, encompassing more than 120 patients, showed improvements across multiple efficacy endpoints including overall response rate and progression-free survival, with performance exceeding the currently marketed HIF-2α inhibitor class.

The company retains worldwide rights to casdatifan except in Japan and select Asian territories, where Taiho Pharmaceutical Co., Ltd. holds an option executed in October 2025. Multiple data readouts are anticipated throughout 2026.

Portfolio Expansion and Runway Assessment

Beyond casdatifan, Arcus maintains a diverse oncology portfolio anchored by quemliclustat, a CD73 inhibitor that completed enrollment in the late-stage PRISM-1 pancreatic cancer trial. Registrational data evaluating quemliclustat plus gemcitabine/nab-paclitaxel against chemotherapy alone are expected in 2027.

The company is also expanding its inflammatory and autoimmune (I&A) disease pipeline with five small-molecule oral programs targeting MRGPRX2, TNF, CCR6, CD89, and CD40L—mechanisms currently dominated by injectable therapies. A small molecule targeting MRGPRX2 is projected to enter clinical development in 2026.

With approximately $1 billion in cash and investments on hand, Arcus projects sufficient funding to support planned operations through at least mid-2028, though the STAR-221 discontinuation presents a near-term headwind requiring investor reassessment of the company’s clinical execution risk and pipeline productivity.